Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00657319

Enrollment

3495

Registered

2008-04-14

Start date

2007-10-31

Completion date

2008-04-30

Last updated

2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

Interventions

DRUGbiphasic insulin aspart 30

The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months * Analogue premix administration for the last 6 months

Exclusion criteria

* Known or suspected allergy to insulin aspart * Newly diagnosed diabetes

Design outcomes

Primary

Measure	Time frame
HbA1C	6 months

Secondary

Measure	Time frame
General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)	6 months

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026